Evidence from a meta-analysis study revealed a significantly high serum LOXL 2 concentration in patients with colorectal cancer (CRC), attributed to increase in Lysyl oxidase-dependent catalytic activity [34,45]. This evidence concerns the gene LOX and colorectal carcinoma.